CD39 (ENTPD1) in tumors: a potential therapeutic target and prognostic biomarker

被引：4

作者：

Li, Cuicui ^{[1
]}

Zhang, Litian ^{[1
]}

Jin, Qiqi ^{[1
]}

Jiang, Haoyun ^{[1
]}

Wu, Chongyang ^{[1
]}

机构：

[1] Lanzhou Univ, Dept Gastroenterol, Hosp 2, Lanzhou 730000, Peoples R China

来源：

BIOMARKERS IN MEDICINE | 2023年 / 17卷 / 12期

基金：

中国国家自然科学基金;

关键词：

adenosine; biomarker; CD39; CD8(+) TIL; exhaustion; immunosuppression; PD-1; tumor microenvironment; CD8; T-CELLS; ECTONUCLEOTIDASES CD39; IMMUNE-RESPONSES; PD-L1; EXPRESSION; ADENOSINE; RECEPTOR; CD73; METABOLISM; SUBSETS; CANCER;

D O I：

10.2217/bmm-2023-0202

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

As a regulator of the dynamic balance between immune-activated extracellular ATP and immunosuppressive adenosine, CD39 ectonucleotidase impairs the ability of immune cells to exert anticancer immunity and plays an important role in the immune escape of tumor cells within the tumor microenvironment. In addition, CD39 has been studied in cancer patients to evaluate the prognosis, the efficacy of immunotherapy (e.g., PD-1 blockade) and the prediction of recurrence. This article reviews the importance of CD39 in tumor immunology, summarizes the preclinical evidence on targeting CD39 to treat tumors and focuses on the potential of CD39 as a biomarker to evaluate the prognosis and the response to immune checkpoint inhibitors in tumors.

引用

页码：563 / 576

页数：14

共 50 条

[1] ENTPD1/CD39 is a promising therapeutic target in oncology
Bastid, J.
Cottalorda-Regairaz, A.
Alberici, G.
Bonnefoy, N.
Eliaou, J-F
Bensussan, A.
ONCOGENE, 2013, 32 (14) : 1743 - 1751
[2] ENTPD1/CD39 is a promising therapeutic target in oncology
J Bastid
A Cottalorda-Regairaz
G Alberici
N Bonnefoy
J-F Eliaou
A Bensussan
Oncogene, 2013, 32 : 1743 - 1751
[3] CD39/ENTPD1: At the interface between innate and adaptive immunity
Robson, Simon C.
Keiichi, Enjyoji
Wu, Yan
Beldi, Guido
Banz, Yara
Kunzli, Beat
Sun, Xiaofeng
Friedman, David
Deaglio, Silvia
Dwyer, Karen
Strom, Terry
PURINERGIC SIGNALLING, 2008, 4 : S3 - S3
[4] Deletion of Cd39/Entpd1 results in hepatic insulin resistance
Enjyoji, Keiichi
Kotani, Ko
Thukral, Chandrashekar
Blumel, Benjamin
Sun, Xiaofeng
Wu, Yan
Imai, Masato
Friedman, David
Csizmadia, Eva
Bleibel, Wissam
Kahn, Barbara B.
Robson, Simon C.
DIABETES, 2008, 57 (09) : 2311 - 2320
[5] Expression of ENTPD1/CD39 is protective in a mouse model of biliary fibrosis
Feldbruegge, Linda
Mitsuhashi, Shuji
Csizmadia, Eva
Sun, Xiaofeng
Schmelzle, Moritz
Robson, Simon C.
HEPATOLOGY, 2015, 62 : 892A - 892A
[6] IDENTIFICATION OF NEW POTENTIAL THERAPEUTIC TARGETS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: ENTPD1 (CD39) AND 5NTE1 (CD73)
Finn, Jonathan D.
van Baarsen, Lisa
van Ittersum, Jan
Braam, Ciska
Lebre, Maria C.
Tak, Paul P.
Vervoordeldonk, Margriet J.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : A66 - A66
[7] Deletion of Cd39/Entpd1 promotes spontaneous development of hepatocellular carcinoma (HCC)
Wu, Yan
Sun, Xiaofeng
Imai, Masato
Sultan, Babar
Csizmadia, Eva
Usheva, Anny
Robson, Simon
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A74 - A74
[8] Modulation of RAS/ERK signaling by CD39/ENTPD1 during liver regeneration
Wu, Y
Sun, XF
Imai, M
Sultan, B
Csizmadia, E
Enjyoji, K
Jackson, SW
Usheva, A
Robson, SC
HEPATOLOGY, 2005, 42 (04) : 643A - 643A
[9] Regulated Catalysis of Extracellular Nucleotides by Vascular CD39/ENTPD1 Is Required for Liver Regeneration
Beldi, Guido
Wu, Yan
Sun, Xiaofeng
Imai, Masato
Enjyoji, Keiichi
Csizmadia, Eva
Candinas, Daniel
Erb, Laurie
Robson, Simon C.
GASTROENTEROLOGY, 2008, 135 (05) : 1751 - 1760
[10] High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma
Zhang, Bin
Cheng, Bo
Li, Feng-Sheng
Ding, Jian-Hua
Feng, Ying-Ying
Zhuo, Guang-Zuan
Wei, Hua-Feng
Zhao, Ke
TUMOR BIOLOGY, 2015, 36 (12) : 9411 - 9419

← 1 2 3 4 5 →